Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALECNASDAQ:FATENASDAQ:FGENNASDAQ:THTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.07-3.6%$1.16$0.87▼$6.78$110.99M0.76830,629 shs3.17 million shsFATEFate Therapeutics$0.96-4.0%$1.01$0.66▼$5.92$110.02M2.322.24 million shs2.28 million shsFGENFibroGen$0.30+0.2%$0.32$0.18▼$1.53$30.30M0.862.08 million shs894,777 shsTHTXTheratechnologies$2.53-3.4%$2.08$1.12▼$3.13$116.33M0.56805,101 shs329,893 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-3.60%+4.39%+9.09%-35.93%-79.92%FATEFate Therapeutics-4.00%-4.00%+3.86%-24.41%-77.25%FGENFibroGen+0.20%-8.01%0.00%-42.42%-74.58%THTXTheratechnologies-3.44%-8.17%-1.56%+55.21%+100.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.6244 of 5 stars3.12.00.04.51.81.70.6FATEFate Therapeutics4.4554 of 5 stars4.13.00.04.72.41.70.6FGENFibroGen4.4791 of 5 stars3.35.00.04.71.63.30.6THTXTheratechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.14Hold$4.00273.83% UpsideFATEFate Therapeutics 2.22Hold$4.14331.55% UpsideFGENFibroGen 2.50Moderate Buy$10.003,234.44% UpsideTHTXTheratechnologies 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest FGEN, FATE, THTX, and ALEC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025FATEFate TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.005/14/2025FATEFate TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.005/14/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/13/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.004/11/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/1/2025FGENFibroGenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/18/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/7/2025ALECAlectorMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight$3.00 ➝ $1.503/6/2025FATEFate TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$5.00 ➝ $3.003/6/2025FATEFate TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$5.00 ➝ $4.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$88.34M1.21N/AN/A$1.41 per share0.76FATEFate Therapeutics$13.63M8.07N/AN/A$3.74 per share0.26FGENFibroGen$29.62M1.02N/AN/A($1.87) per share-0.16THTXTheratechnologies$88.67M1.31N/AN/A($0.45) per share-5.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$130.39M-$1.23N/AN/AN/A-257.54%-108.77%-27.03%N/AFATEFate Therapeutics-$160.93M-$1.64N/AN/AN/A-1,325.43%-45.88%-33.95%N/AFGENFibroGen-$284.23M-$0.48N/AN/AN/A-67.66%N/A-36.17%N/ATHTXTheratechnologies-$23.96M-$0.08N/A36.14N/A-3.75%N/A-4.31%7/9/2025 (Estimated)Latest FGEN, FATE, THTX, and ALEC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025FATEFate Therapeutics-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million5/12/2025Q1 2025FGENFibroGen$0.03-$0.16-$0.19$0.05$2.00 million$2.70 million3/17/2025Q4 2024FGENFibroGen-$0.08-$0.08N/A$0.18$24.91 million$3.14 million3/5/2025Q4 2024FATEFate Therapeutics-$0.44-$0.31+$0.13-$0.44$1.57 million$1.86 million2/26/2025Q4 2024ALECAlector-$0.61-$0.02+$0.59-$0.02$20.41 million$54.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlectorN/A3.293.29FATEFate TherapeuticsN/A8.298.29FGENFibroGenN/A1.281.16THTXTheratechnologiesN/A1.080.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%FATEFate Therapeutics97.54%FGENFibroGen72.71%THTXTheratechnologiesN/AInsider OwnershipCompanyInsider OwnershipALECAlector9.10%FATEFate Therapeutics5.00%FGENFibroGen3.07%THTXTheratechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector27099.99 million89.02 millionOptionableFATEFate Therapeutics550114.60 million108.20 millionOptionableFGENFibroGen570101.04 million98.78 millionOptionableTHTXTheratechnologies14045.98 millionN/AOptionableFGEN, FATE, THTX, and ALEC HeadlinesRecent News About These CompaniesTheratechnologies (NASDAQ:THTX) and NexImmune (NASDAQ:NEXI) Financial AnalysisMay 11, 2025 | americanbankingnews.comTheratechnologies (NASDAQ:THTX) Trading Up 0.5% - Here's WhyMay 10, 2025 | marketbeat.comTheratechnologies (NASDAQ:THTX) Trading Up 0.5% - Here's What HappenedMay 10, 2025 | marketbeat.comTheratechnologies announces annual shareholder meetingMay 4, 2025 | uk.investing.comTheratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIVMay 2, 2025 | globenewswire.comTheratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 OfferApril 18, 2025 | seekingalpha.comIs Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?April 18, 2025 | msn.comResearch Analysts Set Expectations for THTX FY2025 EarningsApril 18, 2025 | marketbeat.comWhat is Leede Financial's Estimate for THTX FY2026 Earnings?April 17, 2025 | marketbeat.comShort Interest in Theratechnologies Inc. (NASDAQ:THTX) Rises By 2,740.1%April 16, 2025 | marketbeat.comTheratechnologies to further evaluate potential sale of the companyApril 16, 2025 | markets.businessinsider.comTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | financialpost.comTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | globenewswire.comTheratechnologies Engages in Exclusive Acquisition TalksApril 15, 2025 | tipranks.comSoleus Capital Issues Letter to The Board of TheratechnologiesApril 12, 2025 | financialpost.comSoleus Capital Issues Letter to The Board of TheratechnologiesApril 12, 2025 | businesswire.comTheratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the CompanyApril 11, 2025 | globenewswire.comFuture Pak submits proposals to acquire TheratechnologiesApril 11, 2025 | msn.comFuture Pak Submits Proposals to Acquire Theratechnologies Inc. ...April 11, 2025 | gurufocus.comFuture Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total ValueApril 11, 2025 | businesswire.comTheratechnologies Stock Plummets On Disappointing Q1 Earnings, Full Year Forecast: Retail Sentiment SoursApril 9, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFGEN, FATE, THTX, and ALEC Company DescriptionsAlector NASDAQ:ALEC$1.07 -0.04 (-3.60%) As of 05/14/2025 04:00 PM EasternAlector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Fate Therapeutics NASDAQ:FATE$0.96 -0.04 (-4.00%) As of 05/14/2025 04:00 PM EasternFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.FibroGen NASDAQ:FGEN$0.30 +0.00 (+0.20%) As of 05/14/2025 04:00 PM EasternFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Theratechnologies NASDAQ:THTX$2.53 -0.09 (-3.44%) As of 05/14/2025 04:00 PM EasternTheratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
